抗感染症薬市場 - 分析、市場規模、シェア、動向、予測：2021年～2027年
Anti-Infective Agents Market, By Type, By Distribution Channel, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2021-2027
|抗感染症薬市場 - 分析、市場規模、シェア、動向、予測：2021年～2027年|
発行: AnalystView Market Insights
ページ情報: 英文 268 Pages
Anti-Infective Agents Market, By Type (Anti-Bacterial, Antifungal, and Anti-Viral Agents), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, E-Commerce, and Retail Pharmacies), and By Geography (EU, NA, APAC, LATAM, and MEA) - Analysis, Size, Share, Trends, & Forecast from 2021-2027.
The global anti-infective agents market was valued at USD 113.8 billion by 2019, growing with 4.8% CAGR during the forecast period, 2021-2027.
The medicines that obstruct the spread of an infectious organism or kill the infectious microbe's outright are entitled as anti-infective. Anti-infective comprises antibiotics, antifungals, antimalarial, antivirals, etc. It plays an important role in revolutionizing the healthcare industry as it offers the treatment of minor infections and serious infectious diseases like tuberculosis (TB) and pneumonia. Besides these, it offers vital immune-suppressive treatment to patients with cancer and is used during complex surgeries or routine procedures that have a high risk of serious infections. As per the World Health Organization (WHO), September 2019, there were more than 50 antibiotics and combinations (with a new therapeutic entity) along with 10 biologics under the clinical pipeline that are targeting the WHO priority pathogens, TB and C.difficile. The major ones include Lascufloxacin, Cefiderocol, Zoliflodacin, Gepotidacin, among others.
Rising prevalence of infectious diseases such as hospital-acquired infections, COVID-19, and sexually transmitted infections (STIs) is one of the prime factors acknowledging the global anti-infective agent market growth. For instance, as per recent developments in regards to the count of confirmed COVID-19 cases (WHO data, 19th July 2020), around 14,043,176 people were affected by this deadly virus. Furthermore, 216 countries are affected by this infectious disease along with the count of total confirmed demise cases to be 597 583. Hence, the above-mentioned pointer serves to be the key determiner boosting the growth of the global market.
Moreover, the increasing funding from the government for the R&D activities related to the development of the COVID vaccine and the implementation of outstanding marketing strategies of the key players in the industry are expected to offer lucrative growth opportunities. For instance, in July 2020, the U.S. government granted US$1.6 billion to the vaccine development company Novavax, Inc. for cover testing, commercialization, and manufacturing of a potential coronavirus vaccine. The aim of this strategy was to deliver 100 million doses of coronavirus cure by January 2021. Thus, research analysts of AnalystView Market Insights opine that the anti-infective agent industry will continue to grow, owing to the favorable government initiatives coupled with new product developments.
On the contrary, the expensive research and development cost and intense competition among generic drug manufacturers are likely to obstruct the global business. Lack of awareness about the benefits and availability of drugs for infectious diseases in developing regions also serves to be the global anti-infective agent market challenge, decreasing the overall product demand.
Depending upon types, the global business is categorized into antibacterial agents, antifungals agents, and antivirals agents. The antibacterial market is sub-categorized into the type and route of administration. The antibacterial category comprises of Fluoroquinolones, Macrolides, Carbapenem, Penicillin, and Cephalosporins. The antifungals segment comprises Azoles, Polyenes, and Echinocandins. Furthermore, the antivirals are broadly fragmented into DNA polymerase inhibitors, protease inhibitors, neuraminidase inhibitors, and reverse transcriptase inhibitors.
The global market is dominated by the anti-bacterial agent, accounting for the rising number of prescriptions as per the current scenario coupled with the availability of a growing count of FDA approved drugs. For instance, in November 2019, the Food and Drug Administration approved 48 novel drugs, including that of antibacterial, antivirals, and anti-fungal. The list comprises Pretomanid tablets, Recarbrio, Avaclyr, and several others. The first one is extensively used for the treatment of non-responsive multidrug-resistant tuberculosis, whereas the last one is capable of curing inflammation of the cornea of the eye called acute herpetic keratitis.
Distribution Channel Takeaway
The distribution channel is categorized into hospital pharmacies, specialty pharmacies, e-commerce, and retail pharmacies. The hospital segment dominates the industry, owing to the increasing count of hospitals globally. As per the American Hospital Association, in 2020, the total number of all the U.S. hospitals accounts for 6,146. Similarly, the Center for Disease Dynamics, Economics & Policy (CDDEP) revealed that, in India, the total number of hospitals is 69,265, including both private and public hospitals.
Also, the intensive care of the patients in hospitals following by quick reimbursement aids in boosting the segment growth. Easy accessibility of drugs is also responsible for creating growth opportunities; thereby supporting the revenue growth over other distribution channels. Besides, the increasing per capita income coupled with the improving healthcare system in developing countries is also expected to shoot the market growth to the maximum verge of profits.
North America leads the regional segment, owing to the presence of developed health care infrastructure coupled with the rising awareness about the benefits of the agents among end-users. Furthermore, the favorable reimbursement policies from the government of the developed nations such as North America and Europe are likely to influence industrial growth in a positive direction. For instance, the Center for Connected Health Policy (CCHP) updated its State Telehealth Laws & Reimbursement Policies, Fall 2019, covers the reimbursement of treatment opted for infectious diseases, along with trauma, burn, cardiology related telehealth coverage services.
Asia Pacific anti-infective agent market, in the same shoes, holds a significant share and is expected to grow at the fastest CAGR. Increasing investment by generic drug manufacturers and improving healthcare infrastructure are likely to shoot the growth with maximum profits.
The sudden outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from China has diverted the focus of all the scientists and healthcare professionals towards the discovery of the cure. And, the global spread of COVID has now accelerated numerous ongoing researches for the discovery of a vaccine. One such study, named "Possible Therapeutic Agents for COVID-19: a comprehensive review", published in May 2020, covered the application of therapeutics that relieves the patients. As per the study, drugs like Ribavirin and Favipiravir can be used to cure COVID, as these drugs are antiviral. The former one has antiviral activity against hepatitis C virus, respiratory syncytial virus, and viral hemorrhagic fevers; whereas the latter one showed antiviral action against yellow fever, influenza A H1N1, and Ebola. However, still, no drug has been approved by the FDA that serves to be the appropriate cure. Henceforth, the above-mentioned indicators are the key determiners that have directly affected the growth of the global market.
Key Vendor Takeaway
The leading players of the market include Abbott, Astellas Pharma Inc., Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi. The proposed study offers a detailed profiling of players, and also includes useful insights that would help existing companies to increase revenue shares and new players willing to enter the market and thus help them in the decision-making process.
To participate and compete well in the industry, most of the companies are expanding their product portfolios and engaged in strategic collaborations by focusing on untapped opportunities. For instance, in July 2020, Nabriva Therapeutics plc announced the collaboration with the subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA. The terms of the collaboration included the marketing and distribution of SIVEXTRO (Tedizolid Phosphate Tablet) in the U.S. and certain of its territories.
The prominent players are also implementing excellent marketing strategies such as mergers, and acquisitions, to gain greater market share. For instance, in July 2020, Nabriva Therapeutics plc announced its partnership with Sunovion Pharmaceuticals Canada Inc. As per the collaboration, XENLETA will be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year - 2016 to 2018
Base Year - 2019
Estimated Year - 2020
Projected Year - 2021 to 2027
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTI-INFECTIVE AGENTS MARKET KEY PLAYERS
Astellas Pharma Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY TYPE
Market, by Types
Market, by Route of Administration
Market, by Types
Market, by Route of Administration
Market, by Types
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Market, by Route of Administration
Others (Antiprotozoal, Anthelminthic etc.)
GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY DISTRIBUTION CHANNEL
GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA